0.71
Schlusskurs vom Vortag:
$0.7148
Offen:
$0.7076
24-Stunden-Volumen:
3.04M
Relative Volume:
1.23
Marktkapitalisierung:
$119.48M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-0.4863
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
+10.59%
1M Leistung:
+14.94%
6M Leistung:
-44.53%
1J Leistung:
-59.43%
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
0.71 | 119.48M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
2024-09-30 | Fortgesetzt | BTIG Research | Buy |
2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
2022-05-31 | Fortgesetzt | Jefferies | Hold |
2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-03-14 | Herabstufung | Stifel | Buy → Hold |
2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
2021-09-10 | Eingeleitet | BofA Securities | Neutral |
2021-06-28 | Hochstufung | Stifel | Hold → Buy |
2021-05-18 | Fortgesetzt | Goldman | Neutral |
2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
2021-01-06 | Eingeleitet | Stifel | Hold |
2020-09-14 | Eingeleitet | JP Morgan | Neutral |
2020-06-10 | Herabstufung | CFRA | Hold → Sell |
2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
2019-10-24 | Eingeleitet | Oppenheimer | Perform |
2019-10-08 | Herabstufung | Goldman | Buy → Sell |
2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
2018-12-13 | Eingeleitet | Goldman | Buy |
2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
2018-04-06 | Bestätigt | Mizuho | Buy |
2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com
Nektar: Q1 Earnings Snapshot - The Washington Post
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timelines | NKTR Stock News - GuruFocus
Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses Estimate, Revenue Falls Short at $10.5 Million - GuruFocus
Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c - StreetInsider
Nektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock News - GuruFocus
Nektar Therapeutics Q1 Loss Increases, Misses Estimates - Nasdaq
Nektar Therapeutics Reports First Quarter 2025 Financial Results - PR Newswire
Unmet Needs in Atopic Dermatitis and the Impact of Roflumilast Cream, with Raj Chovatiya, MD, PhD - HCPLive
Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com
Nektar Therapeutics's Earnings: A Preview - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets - Longview News-Journal
Nektar to Announce Financial Results for the First Quarter on Th - GuruFocus
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets | NKTR Stock News - GuruFocus
Upcoming Nektar Q1 2025 Earnings Call: CEO Howard Robin to Present Financial Results May 8 - Stock Titan
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com
Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug - MSN
Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq
Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (NKTR) - MSN
Sector Update: Health Care - TradingView
Jefferies Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance
Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance
Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha
Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga
Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - marketscreener.com
Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India
Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider
Jefferies Upgrades Nektar (NKTR) with Optimistic Outlook on Phase 2b Study | NKTR Stock News - GuruFocus
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nektar Therapeutics-Aktie (NKTR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Wilson Mark Andrew | Chief Legal Officer |
Feb 19 '25 |
Sale |
1.01 |
11,040 |
11,150 |
324,292 |
ROBIN HOWARD W | President & CEO |
Feb 19 '25 |
Sale |
1.01 |
23,774 |
24,012 |
1,086,901 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):